Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

58
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
58
Drug Delivery Systems: Different Types01:27

Drug Delivery Systems: Different Types

131
Conventional oral drug products, termed immediate-release (IR) formulations, are engineered to promptly release their active pharmaceutical ingredient (API) upon ingestion, typically in tablets or capsules. This rapid release often results in swift drug absorption and consequent pharmacodynamic effects, although the timing and intensity can vary depending on the drug's properties. Prodrugs within these formulations require metabolic conversion to activate their pharmacodynamic effects,...
131
Site-Targeted Drug Delivery Systems: Polymeric Carriers01:24

Site-Targeted Drug Delivery Systems: Polymeric Carriers

65
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
65
The Tumor Microenvironment02:17

The Tumor Microenvironment

8.0K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
8.0K
Modified-Release Drug Delivery Systems: Classification01:23

Modified-Release Drug Delivery Systems: Classification

129
Modified-release drug delivery systems improve drug efficacy and minimize side effects by controlling the rate and location of drug release. These systems fall into three categories: rate-programmed, stimuli-activated, and site-targeted.Rate-programmed systems release drugs at a predetermined rate, maintaining consistent therapeutic levels and reducing fluctuations that could lead to toxicity or subtherapeutic effects. These systems use polymeric matrices, reservoir-based designs, or osmotic...
129
Modified-Release Drug Delivery Systems: Overview01:19

Modified-Release Drug Delivery Systems: Overview

74
Modified-release dosage forms are designed to address the limitations of drugs with short biological half-lives. These forms maintain stable therapeutic drug concentrations over extended periods, reducing the need for frequent dosing. A consistent drug level helps minimize peak-trough fluctuations, which can reduce adverse effects, lower the risk of drug resistance, and improve overall treatment effectiveness.One common type of modified-release form is the extended-release (ER) formulation. ER...
74

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A safe and effective mucosal RSV vaccine in mice consisting of RSV phosphoprotein and flagellin variant.

Cell reports·2021
Same author

In vivo liquid biopsy for glioblastoma malignancy by the AFM and LSPR based sensing of exosomal CD44 and CD133 in a mouse model.

Biosensors & bioelectronics·2021
Same author

Genomic evidence for the Chinese mountain cat as a wildcat conspecific (<i>Felis silvestris bieti</i>) and its introgression to domestic cats.

Science advances·2021
Same author

Optimization and visualization of phase modulation with filtered and amplified maximal-length sequence for SBS suppression in a short fiber system: a theoretical treatment.

Optics express·2021
Same author

The nearly complete genome of Ginkgo biloba illuminates gymnosperm evolution.

Nature plants·2021
Same author

All Binder-Free Electrodes for High-Performance Wearable Aqueous Rechargeable Sodium-Ion Batteries.

Nano-micro letters·2021

Related Experiment Video

Updated: Mar 6, 2026

Microfluidic Device for Recreating a Tumor Microenvironment in Vitro
16:18

Microfluidic Device for Recreating a Tumor Microenvironment in Vitro

Published on: November 20, 2011

12.1K

Current Multistage Drug Delivery Systems Based on the Tumor Microenvironment.

Binlong Chen1, Wenbing Dai2, Bing He1

  • 1Beijing Key Laboratory of Molecular Pharmaceutics and New Drug Delivery Systems, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China; State Key Laboratory of Natural and Biomimetic Drugs, Beijing 100191, China.

Theranostics
|March 4, 2017
PubMed
Summary

Multistage drug delivery systems (Ms-DDS) overcome tumor complexity by adapting to the microenvironment for enhanced drug delivery and therapy. These advanced systems offer improved tumor penetration and cellular uptake for better treatment outcomes.

Keywords:
activatable nanoparticlesdrug delivery systemsmultistagestimuli-responsivetumor microenvironment

More Related Videos

Preparation and Characterization of Lipophilic Doxorubicin Pro-drug Micelles
09:56

Preparation and Characterization of Lipophilic Doxorubicin Pro-drug Micelles

Published on: August 2, 2016

15.6K
Generation of Heterogeneous Drug Gradients Across Cancer Populations on a Microfluidic Evolution Accelerator for Real-Time Observation
10:24

Generation of Heterogeneous Drug Gradients Across Cancer Populations on a Microfluidic Evolution Accelerator for Real-Time Observation

Published on: September 19, 2019

6.8K

Related Experiment Videos

Last Updated: Mar 6, 2026

Microfluidic Device for Recreating a Tumor Microenvironment in Vitro
16:18

Microfluidic Device for Recreating a Tumor Microenvironment in Vitro

Published on: November 20, 2011

12.1K
Preparation and Characterization of Lipophilic Doxorubicin Pro-drug Micelles
09:56

Preparation and Characterization of Lipophilic Doxorubicin Pro-drug Micelles

Published on: August 2, 2016

15.6K
Generation of Heterogeneous Drug Gradients Across Cancer Populations on a Microfluidic Evolution Accelerator for Real-Time Observation
10:24

Generation of Heterogeneous Drug Gradients Across Cancer Populations on a Microfluidic Evolution Accelerator for Real-Time Observation

Published on: September 19, 2019

6.8K

Area of Science:

  • Biomedical Engineering
  • Nanotechnology
  • Cancer Therapy

Background:

  • Traditional tumor-targeted drug delivery faces challenges due to tumor biological complexity and nano-system design limitations.
  • The enhanced permeability and retention (EPR) effect and receptor-mediated endocytosis have limitations in achieving effective tumor targeting.
  • Multistage drug delivery systems (Ms-DDS) offer a promising alternative by adapting to diverse biological environments.

Purpose of the Study:

  • To review the mechanisms and recent advances in multistage drug delivery systems (Ms-DDS) for tumor therapy and imaging.
  • To highlight the advantages of Ms-DDS in overcoming the limitations of traditional drug delivery systems.
  • To discuss the potential and future prospects of multi-stimuli responsive Ms-DDS.

Main Methods:

  • Review of literature on multistage nanoparticle systems and their response to tumor microenvironment stimuli.
  • Analysis of how Ms-DDS modify physicochemical properties (size, hydrophobicity, zeta potential) in response to physiological differences.
  • Discussion of mechanisms including deeper tumor penetration, enhanced cellular uptake, controlled drug release, and endosomal escape.

Main Results:

  • Ms-DDS demonstrate adaptability to tumor microenvironment and intracellular conditions, leading to improved drug delivery.
  • Multi-stimuli responsive Ms-DDS show enhanced therapeutic efficacy by delivering drugs to specific tumor sites, cells, and organelles.
  • These systems offer potential for maximizing drug quantity at therapeutic targets.

Conclusions:

  • Ms-DDS represent a significant advancement in tumor-targeted drug delivery, offering superior control and efficacy.
  • The multi-stimuli responsive nature of these systems is key to their enhanced performance in complex tumor environments.
  • Ms-DDS hold considerable promise for future cancer therapy and diagnostic applications.